Most articles on microarray technology, particularly reviews, begin with some over-reaching statement on their potential to illuminate the biological world. While resisting this temptation, we must acknowledge the increasing power of high-throughput expression profiling using high-density arrays. A quick Medline search of all papers referenced with the term \'microarray\' shows an exponential increase since the first paper describing the approach by Pat Brown\'s group six years ago \[[@B1]\] (Figure [1](#F1){ref-type="fig"}). A calculated projection based on the number of papers this year to date predicts a total of around 500 microarray publications for 2001. The technology is quickly becoming a mainstay in the \'array\' of tools available to the molecular biologist, and we expect it to be broadly applicable to our favorite genetically tractable organism, the laboratory mouse.
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Available arrays and clone sets
===============================

The production of mouse microarrays has lagged somewhat behind the production of arrays from humans and from those model organisms for which full genome sequence is available, such as yeast or *Caenorhabditis elegans.* Oligonucleotide-based arrays from sources such as Affymetrix (Santa Clara, CA, USA) have been in production for a number of years, but their high cost has been a barrier to widespread general use in academia. The cDNA array effort has been hampered largely by the scarcity of large, well-annotated cDNA clone sets from mouse tissues. Fortunately, a number of recent publications have addressed this issue. Minoru Ko at the National Institute on Aging (NIA; National Institutes of Health, Bethesda, MD, USA) has developed a 15,247 clone set derived from mice largely at early developmental time points, with libraries covering stages from the early blastocyst to embryonic day (E) 7.5 (for which there are embryo and ectoplacental cone samples) \[[@B2]\]. This set will have added to it later this year a further 11,000 clones derived from sequencing of similar libraries, and libraries from trophoblast stem cells, hematopoietic stem cells, embryonic stem cell line R1, newborn heart, brain, and kidney, and mesenchymal stem cells (M.S. Ko, personal communication). The set has been sequence-verified \[[@B3]\] and is cloned into a vector system with binding sites for both SP6 and T7 polymerases flanking the insert, so that riboprobes for *in situ* hybridization studies can be generated directly. The average insert size is estimated to be roughly 1.5 kilobases (and we have found this generally to be the case). The clone set has been widely distributed to a number of centers for microarray printing, including our own local facility at the Ontario Cancer Institute \[[@B4]\]; these centers are currently in various stages of production \[[@B5]\].

The RIKEN Institute in Japan has also recently described a 21,076 cDNA clone set thought to represent at least 12,890 unique genes, which was generated from sequencing just under one million total expressed sequence tags (ESTs) \[[@B6],[@B7]\]. This group of clones has the major advantage that more than 60% are full-length cDNAs, because of the methods used in library construction. Also, these clones are derived from a broad spectrum of adult and developmental stages of various tissues, which provides a nice complement to the much earlier stages used to derive cDNA libraries for the NIA 15,247 clone set. A quick analysis indicates that there are at least 26,700 non-redundant clones between the two sets. Although arrays have been generated from these clones by RIKEN (see below), they have not yet been made widely available to the scientific community. As a result, we will probably see more work initially in the literature that uses microarrays printed from the NIA set in combination with custom-derived clones.

Arguably the most comprehensive mouse arrays available are the Murine Genome U74 Set from Affymetrix. This group of three arrays provides coverage of roughly 36,000 mouse genes, of which about 30,000 are known only as ESTs. As mentioned previously, however, there has not been widespread use of these arrays because of the prohibitively high cost of the arrays and the associated scanning hardware. But given the advantages of oligonucleotide-based arrays for interrogating multiple regions of a transcript or alternatively spliced forms, in addition to their flexibility for array design, we expect the adoption of this platform for array technology to increase in the future. Operon Technologies (Alameda, CA, USA) has recently introduced a mouse 7,000 oligonucleotide set that is available for purchase for array printing;the size of this and similar sets is likely to increase substantially in the near future.

In general, given the advances in size and availability of sets of mouse cDNA clones and oligonucleotides, we foresee an increase in the number of centers making the initial investment to start microarray facilities and capitalize on this technology. Printing cDNAs has the advantage of replicating directly the microarrays printed elsewhere, although it does have the disadvantage of laborious amplification of cDNA inserts for printing and difficulties in managing a large number of clones. Oligonucleotide arrays eliminate some of these problems and offer a number of flexibility advantages in array printing, but they come with higher initial start-up costs. Although we are moving in the direction of a \'whole-genome microarray\' as we approach the completion of the mouse genome-sequencing project, it is likely that many groups will focus on smaller, custom, gene groupings to reduce both costs and the engineering difficulties associated with printing arrays of higher density.

Coping with data deluge
=======================

Although to date only a small number of mouse microarray studies have been published in the literature, we expect a tidal wave of papers over the next two to three years as this technology becomes widely available. Minoru Ko\'s group has described experiments using nylon arrays printed from their NIA 15,247 clone set. In profiling comparisons of E12.5 placenta and whole embryos, they identified 720 genes that appeared (statistically, from triplicate measurements) to be upregulated in the placenta \[[@B8]\]. Of these, 181 were represented by novel ESTs not previously known to be placentally enriched, increasing the total number of genes known to be highly expressed in the placenta by about five-fold. The placenta-specific expression pattern was confirmed for one of these novel genes (H3018Bo6) by *in situ* hybridization; homology searches suggest that it could be a novel member of the placental growth-related hormone family.

The RIKEN group has created cDNA microarrays printed on glass slides from a set of 18,000 clones enriched for full-length cDNAs. In a recent paper \[[@B9]\], gene expression was profiled in a total of 49 different adult and embryonic tissues. Data were normalized using RNA from E17.5 whole embryos, which has a number of practical advantages as an external reference over using individual tissues, given the ease of RNA preparation from whole embryos and the diversity of expressed genes. Data were then clustered \[[@B10]\] to look at the underlying order in gene expression amongst various tissues. As expected, the observed expression profiles correlated well with the tissues from which cDNAs were originally cloned. Further analysis of expression patterns in the developing nervous system showed unique clusters associated with apoptotic cell death in neural remodeling and with different phases of the cell cycle. In an analysis of expression patterns of metabolic pathways, a separation of enzymes into 78 different synthetic and degradative metabolic pathways was used to look at coordinated regulation of expression patterns \[[@B9]\]. Interestingly, genes were clustered into groups of those ubiquitously expressed and those with tissue-specific patterns. In a more detailed analysis of enzymes in the glycolytic pathway, tissue-specific differences were identified in gene products for glycolytic enzymes derived from muscle versus those present in liver and kidney \[[@B9]\].

Using the Affymetrix system, Zirlinger *et al.* \[[@B11]\] have recently analyzed differential gene expression in selected regions of the brain using arrays containing approximately 34,000 genes. They screened by *in situ* hybridization a series of 33 genes identified to be amygdala-enriched from array experiments and found that a number of them had expression patterns restricted to the subnuclei of the amygdala. Using the earlier Mu11K array, containing 11,000 gene elements, Voehringer *et al.* \[[@B12]\] demonstrated a series of alterations in gene expression in apoptosis-sensitive compared with apoptosis-resistant B-cell lymphoma cell lines before and after irradiation. From these observations, they suggested a model for sensitivity to apoptosis involving induction of transcripts for genes participating in mitochondrial uncoupling and loss of membrane potential.

One of the major stumbling blocks for new users is the processing and management of data once microarray hybridization has been done. The number of both freely available and commercial packages that are user-friendly for performing these functions is rapidly increasing. At our institute, we use a combination of the commercial Quantarray (Packard BioChip Technologies, Billerica, MA, USA) and GenePix (Axon Instruments, Union City, CA, USA) packages to find spots and assign grayscale hybridization intensities. We then use a package developed locally \[[@B13]\] to handle background subtractions and normalizations and to create databases of cumulative experiments for clustering. These are certainly not the only tools available, nor are they necessarily the best, and we anticipate more user-friendly packages for these functions to arrive shortly, given the flurry of activity in the area. What is not yet clear is how best to sort through the data from validated experiments once one has identified groups of genes that are of interest to the individual investigator.

The power of freely distributed raw data
========================================

One of the big benefits of the freely distributed array data accumulating on the web is the ability to do a greater amount of complex experimental work at the computer, as opposed to the wet-lab bench. There are far too many observations in any large-scale microarray study to comment on all of them in the text of a journal article, and the emerging practice of requiring authors to post data on a website allows other investigators to examine portions of the data relevant to their individual interests. For example, as part of an ongoing project examining lung organogenesis, we have downloaded the RIKEN gene expression database \[[@B7]\] and performed some further analysis on the gut-endoderm-derived tissues in the dataset. This was done over a period of days using both commercial and freely available software on a standard desktop computer. As shown in Figure [2a](#F2){ref-type="fig"}, a topography plot of a statistically selected subset of 113 genes in these tissues reveals a number of unique expression patterns. We identified peaks in the plot from embryonic lung stages corresponding to a number of ESTs, including one with homology to the Ras-related protein Rab2. Further analysis of the lung developmental time points demonstrated a number of unique findings. The blade diagram in Figure [2b](#F2){ref-type="fig"} shows the enhanced expression in the embryonic lung of a series of genes compared with adult lung tissue. This group includes a total of 782 ESTs of unknown function. Using conventional Eisen clustering \[[@B10]\] (Figure [2c](#F2){ref-type="fig"}), we found groupings associated with known lung-enriched proteins such as surfactant protein A, in addition to a number of genes that appeared to be enriched at the E16 time point compared with the other lung time points and with whole embryos.

![An example of the use of the RIKEN gene expression database. **(a)** Topography plot of gut-endoderm-derived tissues from the RIKEN mouse dataset. The full dataset for these 14 tissues was filtered by total variance to produce a subset of 113 genes. This subset was clustered two-dimensionally using CLUSTER \[10\], and the resulting gene and sample order used to create the pictured topography plot in MatLab R12 (Mathworks, Natick, MA, USA). **(b)** Blade diagram of lung data from the RIKEN dataset. Asubset of 1,319 genes with the highest total variance was selected across the E16 lung, neonatal day 0 lung, and adult lung experiments. Genes with peaks at the edges of the diagram are enriched in the respective developmental stages compared to the adult sample. **(c)** Clustering of lung-expressed genes. The subset of genes described in (b) was clustered one-dimensionally with the whole embryo experiments using the order of samples shown. **(i)** A cluster containing surfactant protein A, a known lung-enriched gene; **(ii)** a cluster of ESTs enriched in the E16 lung. The RIKEN identification numbers and gene names (if known) are given.](gb-2001-2-7-reviews1019-2){#F2}

We expect the volume of microarray work performed in the mouse to quickly outweigh that of other model organisms for a number of reasons. From a developmental perspective, the mouse is the only genetically tractable model organism that closely resembles humans in the formation of organ systems with similar structure and function to ours. Collecting fresh tissue for RNA analysis at all developmental and adult stages is a relatively simple task. Also, the number of genetic mutants closely resembling human disease processes is dramatically increasing with the expansion of forward-genetic (mutagenesis) screens in the mouse, providing many opportunities to perform genome-wide scans of transcripts varying in a particular model of interest. Wide application of microarray techniques to embryos, tissues, or cells harboring engineered mutations will create an exponential number of permutations and combinations ripe for investigation.

Although the future is bright, there is room for improvement in a number of areas. A working draft copy of the mouse genome sequence will certainly aid in making sense of expression data from novel ESTs. This could potentially narrow down genes of interest to those that have a putative motif or predicted function of interest. As judged by discussion at a recent symposium on statistical aspects of microarray data analysis \[[@B14]\], there is not yet anything resembling consensus amongst statisticians as to the most appropriate methods to deal with array data. One of the overall challenges to statisticians and computer scientists in general will be the development of analysis software that is readily usable by the uninitiated biologist with data from their first experiment in hand. Although many companies currently claim that their products do this and everything else, this has not been the case in our experience. This will no doubt change in the near future, however, given the rapid advancements from academic and commercial activity in the area.
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